US equity futures are soaring after-hours following headlines from STAT news that Gilead Sciences' experimental drug remdesivir is “seeing rapid recoveries in fever and respiratory symptoms.”
Almost all patients were discharged in under than a week, and only two patients died, STAT said, citing comments made this week during a video discussion about trial results with University of Chicago faculty members.
STAT cautions that trials are running at other institutions and full study results can’t yet be determined; Gilead told the news outlet that it’s looking forward to data becoming available.
University of Chicago Medicine recruited 125 people into two late-stage studies, including 113 with severe Covid-19.
Gilead stocks is soaring...
To read more visit Zero Hedge.
